BRCA1 and breast carcinoma: Besides, breast cancer 1 (BRCA1)-deficient cells were sensitized to the BET inhibitor, which reversed the MYC/TXNIP axis by inhibiting the activity of thioredoxin and elevating cellular oxidative stress, causing DNA damage that led to the death of BRCA1-deficient breast cancer cells (30, 31).